CPRD Sprint Heart Failure Study

CPRD are working with Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., (“MSD”) to support delivery of this clinical trial about an experimental medicine, vericiguat (MK-1242) for the treatment of Chronic Heart Failure with Reduced Ejection Fraction.

The Hall Practice is helping CPRD recruiting for this trial. We will invite potentially eligible patients to take part in the trial by sending the study invitation letter by post.